Compare DH & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DH | FHTX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.1M | 360.8M |
| IPO Year | 2021 | 2020 |
| Metric | DH | FHTX |
|---|---|---|
| Price | $1.22 | $5.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $3.43 | ★ $11.71 |
| AVG Volume (30 Days) | ★ 364.0K | 115.3K |
| Earning Date | 05-25-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.28 | 32.48 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $241,521,000.00 | $22,602,000.00 |
| Revenue This Year | N/A | $40.91 |
| Revenue Next Year | $1.21 | $11.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.07 | $2.94 |
| 52 Week High | $4.70 | $6.95 |
| Indicator | DH | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 22.47 | 50.64 |
| Support Level | N/A | $4.44 |
| Resistance Level | $2.96 | $5.85 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 21.64 | 63.86 |
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.